- Company
- Celltrion seeks to expand influence in EUR with Remsima SC
- by Hwang, Byung-woo Jul 5, 2024 05:48am
- Celltrion is expanding to expand the drug’s market share with the addition of Remsima SC’s dosing regimens that followed the EMA’s recommendation for the drug’s marketing authorization. The autoimmune disease treatment Remsima SC recently received final approval from the European Commission (EC) for the 'allowance of additional dosing reg
- Company
- Will the shingles market shift affect NIP?
- by Hwang, Byung-woo Jul 4, 2024 05:52am
- The withdrawal of Zostavax from the shingles market is complicating the calculation of the National&160;Immunization Program. In the government's 'National Immunization Program Priorities' study, there had been a large gap between the priorities of live and recombinant shingles vaccines, but with the number of live shingles vaccine options b
- Company
- MBK Partners to acquire Japan pharma for KRW 3 trillion
- by Kim, Jin-Gu Jul 4, 2024 05:52am
- MBK Partners, the largest private equity firm in South Korea, will acquire Japanese company Alinamin Pharmaceutical for JPY 350 billion (around KRW 3.75 trillion). MBK Partners has been actively pursuing M&A in the biopharmaceutical and healthcare sectors in South Korea and overseas. Within the past year and a half, the company acquired M
- Company
- Camzyos’s reimbursement in KOR will be redeliberated today
- by Eo, Yun-Ho Jul 4, 2024 05:52am
- Reimbursement deliberations for Camzyos, a new drug for obstructive hypertrophic cardiomyopathy (oHCM) that had received a redeliberation decision in the past, will again commence today. According to industry sources, BMS Korea's obstructive hypertrophic cardiomyopathy (oHCM) drug Camzyos (mavacamten) will be presented to the latest Drug R
- Company
- Avastin biosimilars occupy over 40% of Avastin mkt
- by Chon, Seung-Hyun Jul 3, 2024 05:51am
- Homegrown biosimilars are rapidly expanding their influence in the KRW 100 billion-a-year Avastin market. Biosimilars’ sales have increased to exceed 40% in less than 2 years. Samsung Bioepis' Onbevzi led the growth with sales close to the original drug. According to the market research firm IQVIA, the market size of bevacizumab anticancer d
- Company
- KOR, with 12 items, ranks '2nd' in FDA-approved biosimilars
- by Kim, Jin-Gu Jul 3, 2024 05:51am
- The U.S. Food and Drug Administration (FDA) has approved 56 biosimilars as of the first half of this year. Twelve of these were from Korean companies, ranking second after the United States. Until now, companies from the United States, South Korea, Germany, and Swiss dominated the U.S. biosimilar market. Recently, companies from India, Icela
- Company
- Eliquis generics will soon return to market
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- The patent for Eliquis (apixaban), a direct-acting oral anticoagulant (DOAC) worth KRW 80 billion a year, will expire in September. As such, generic versions of Eliquis, which were withdrawn from the market in 2021 due to the Supreme Court's reversed decision, will re-enter the market thereafter. The return of generics is expected to once
- Company
- New drug 'Aquipta' for migraine available for prescriptions
- by Eo, Yun-Ho Jul 3, 2024 05:50am
- The new drug 'Aquipta,' an oral migraine treatment, is becoming available in general hospitals in South Korea. According to industry sources, AbbVie Korea’s Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of the ‘Big 5’ tertiary general
- Company
- CSL Behring’s hemophilia B Tx Idelvion is reimbursed in KOR
- by Kang, Hye-Kyung Jul 3, 2024 05:50am
- CSL Behring Korea's hemophilia B treatment Idelvion (albutrepenonacog alfa,) will be reimbursed by Korea’s national health insurance starting in July for the treatment of adult and pediatric patients. Idelvion is approved for the control and routine prophylaxis of bleeding in adults and pediatric patients and for perioperative management
- Company
- Daewoong and LG Chem launch Humira biosimilar 'Xelenka'
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- Daewoong Pharmaceutical and LG Chem said on July 1st that they have launched 'Xelenka,' a Humira (adalimumab) biosimilar. Daewoong Pharmaceutical and LG Chem signed a distributer agreement for domestic sales earlier. Under the agreement, LG Chem will supply Xelenka to Daewoong Pharmaceutical, and Daewoong will handle domestic sales and
